CCN4 and glioblastoma: Wnt-induced signaling protein 1 (WISP1) is required to maintain glioma stem cells and tumor-supportive TAMs in GBM, implying that inhibiting Wnt/-catenin-WISP1 signaling could improve GBM treatment and clinical outcome [266].